PRKCD and systemic sclerosis: These observations, therefore, indicate a much broader participation of PKC-δ in the pathogenesis of tissue fibrosis and suggest that inhibition of the broad spectrum of its profibrogenic effects may be a novel and effective therapeutic approach for SSc and other fibrosing diseases.